JBJoseph Edgar Blais

Joseph Edgar Blais

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph Edgar Blais has a total of 185 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study

    by Joseph Edgar Blais, Ralph Kwame Akyea, William Harrison, Amy Hai Yan Chan, Wenfang Zhong, Stephen Franklin Weng, Kebede Abera Beyene, Wallis C. Y. Lau, Kenneth K. C. Man, Nadeem Qureshi, et al.

    Background: The cardiovascular and mortality benefits of achieving guideline-recommended concentrations of low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol with statins in primary prevention remain uncertain. Methods and findings: In this new-user cohort study, we used electronic healthcare databases from Hong Kong (HK), New Zealand (NZ) and the United Kingdom (UK) to identify 185,237 patients initiating statins between 1 January 2007 and 31 December 2012 (with follow-up to 31 December 2017) without atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Associations between LDL and non-HDL cholesterol measured within 2 years post-initiation with the outcomes of major adverse cardiovascular events (MACE) or all-cause mortality were assessed in landmark analyses using multivariable Cox regression adjusted for age, sex, hypertension, atrial fibrillation, diabetes mellitus, dyslipidaemia, obesity, smoking, alcohol misuse, rheumatoid arthritis, systemic lupus erythematosus and connective tissue disorders, severe mental illness, antihypertensive drugs, antidiabetic drugs, antiplatelet drugs, and anticoagulant drugs. Estimates were pooled using random-effects meta-analysis. At 2 years, LDL cholesterol was <1.4 mmol/L in 7,084 (3.8%), 1.4–1.7 mmol/L in 21,893 (11.8%), 1.8–2.5 mmol/L in 81,941 (44.2%) and ≥2.6 mmol/L in 74,294 (40.1%) patients. Mean duration of follow-up for the primary outcome of MACE was 6.5 years in HK, 5.6 years in NZ and 5.4 years in UK. versus an LDL cholesterol ≥2.6 mmol/L, adjusted hazard ratios (HR) for MACE were 0.80 (95% CI [0.77,0.83]) for 1.8–2.5 mmol/L, 0.79 (0.66,0.94) for 1.4–1.7 mmol/L and 0.82 (0.60,1.12) for <1.4 mmol/L. Non-HDL cholesterol showed similar estimates for MACE (e.g., HR 0.75, [0.72,0.79] for 2.6–3.3 mmol/L versus ≥3.4 mmol/L). In continuous analysis, the association with MACE was approximately log-linear across achieved LDL and non-HDL cholesterol in HK and the UK, whereas in NZ estimates were less consistent and imprecise at the lowest concentrations. After adjustment for confounding factors, very low LDL (HR 1.06, [0.96,1.16]) and non-HDL cholesterol (HR 0.98, [0.84,1.14]) were not associated with all-cause mortality. Limitations include heterogeneity across cohorts, which may reflect confounding by indication where treatment intensity was guided by cardiovascular risk, and residual confounding from comorbidities, lifestyle interventions and disease severity. Estimates are also conditional on patients having initiated statins, survived to the landmark, and undergone follow-up lipid testing. Conclusions: Lower achieved LDL and non-HDL cholesterol after statin initiation was associated with a reduction in MACE, with limited evidence of an increase in all-cause mortality at very low concentrations after adjustment for confounding. Additional reductions in cardiovascular events could be obtained by achieving guideline-recommended non-HDL cholesterol levels of at least <3.4 mmol/L after statin initiation for primary prevention.

  • Open Access

    Sex-Specific Lipid, Apolipoprotein B, and Lipoprotein(a) Responses to Berberine Based on 2 Randomized Placebo-Controlled Trials

    by Jie V. Zhao, Bing Chen, Yap-Hang Chan, Junmeng Zhang, Yuanqing Xia, Joseph Edgar Blais, Haiyong Chen, Brian Tomlinson, Dennis Kai Ming Ip


  • Completeness of EMERGE guideline reporting in observational studies of PCSK9 inhibitor medication adherence: a study within a systematic review

    by Wenfang Zhong, Cheuk Ying Vanessa Li, Amy Hai Yan Chan, Chuenjid Kongkaew, Joseph Edgar Blais

    Objectives: The objective of this study within a review was to assess the completeness of EMERGE (ESPACOMP Medication Adherence Reporting Guideline) item reporting in observational studies included in a systematic review assessing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor medication adherence in clinical practice. Secondary objectives were to compare the completeness of reporting between studies that explicitly aimed to investigate medication adherence and those that did not, and to identify the relevance of these findings for other systematic reviews. Introduction: The International Society for Medication Adherence published the EMERGE in 2018. Although EMERGE aims to improve and standardize the reporting of research on medication adherence, the extent to which the EMERGE guideline is followed is unknown. Methods: This study within a review included 52 observational studies published after 2018 as full-length articles in the host systematic review. Completeness of reporting for each minimum and additional EMERGE item was categorized as completely reported, incompletely reported, not reported, or not applicable. Studies were grouped according to whether their primary aim was to investigate medication adherence (Group 1) or not (Group 2). The completeness of reporting each EMERGE item was compared between groups using Fisher’s exact test. Additionally, the proportion of completely reported items was compared between the groups using the t-test and Mann-Whitney U test. Results: Among the 4 minimum EMERGE items, item 1d (Describe results for the medication adherence phase) was the most often completely reported (80.8%), while item 1b (Provide a precise operation definition) was the least completely reported (38.5%). Among the additional 17 EMERGE items, item 5b (State whether medication adherence was an eligibility criterion) was completely reported in 98.1% of studies, whereas item 5c (Describe routine care related to the management of medication adherence) was the least frequently reported. Twenty (38.5%) studies were categorized into Group 1 and 32 (61.5%) into Group 2. For all EMERGE items, minimum items, and additional items, the mean proportion of completely reported items in Group 1 was higher than that in Group 2 ( P <0.001). Conclusion: Our findings suggest limited application of EMERGE among authors and journals publishing observational studies on PCSK9 inhibitor medication adherence. Strengthening the visibility and application of EMERGE may enhance the consistency of methodological reporting in future studies of medication adherence. Review registration: SWAR Store https://www.qub.ac.uk/sites/TheNorthernIrelandNetworkforTrialsMethodologyResearch/FileStore/SWARFileStore/SWAR50%20Joseph%20Edgar%20Blais%20(2024%20AUG%2001%201402).pdf (SWAR50)

  • Top Cited Papers
    Open Access

    Adherence to PCSK9 Inhibitors in Clinical Practice

    by Joseph Edgar Blais, Wenfang Zhong, Cheuk Ying Vanessa Li, Chuenjid Kongkaew, Amy Hai Yan Chan


  • Open Access

    Real-world evidence on prescribing patterns and lipid-lowering effectiveness of monoclonal antibody PCSK9 inhibitors from Hong Kong

    by Bingbing Zhu, Yuexi Liao, Qiuyan Yu, David T W Lui, Emmanuel Chun-Ka Wong, Esther W Y Chan, Celine S L Chui, Joseph Edgar Blais


  • Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk

    by Vincent Ka Chun Yan, Joseph Edgar Blais, John-Michael Gamble, Esther Wai Yin Chan, Ian Chi Kei Wong, Eric Yuk Fai Wan

    Whether statins benefit patients with type 2 diabetes mellitus (T2DM) with low predicted 10-year cardiovascular risk is uncertain. To evaluate the effectiveness and safety of statin initiation for primary prevention among adults with T2DM stratified by predicted 10-year risk for cardiovascular disease (CVD). Cohort study using target trial emulation. U.K. primary care using the IQVIA Medical Research Data database. Persons aged 25 to 84 years with a diagnosis of T2DM between 2005 and 2016 and no history of coronary artery disease, myocardial infarction, stroke, heart failure, myopathy, liver disease, rheumatic heart disease, schizophrenia, or cancer. Statin initiation versus noninitiation, with estimation of the observational analogues of the intention-to-treat effect. Statin initiators were propensity score-matched to noninitiators in a 1:4 ratio within 4 QRISK3 strata of 10-year predicted cardiovascular risk: low (<10%), intermediate (10% to 19%), high (20% to 29%), and very high (≥30%). Absolute risk differences (RDs) and risk ratios (RRs) at 10 years of follow-up for all-cause mortality and major CVD, as well as myopathy and liver dysfunction. Statin initiation was associated with reductions in all-cause mortality and major CVD across QRISK3 strata. In the low-risk stratum, RDs and RRs were -0.53% (95% CI, -0.90% to -0.08%) and 0.80 (95% CI, 0.67 to 0.97), respectively, for all-cause mortality and -0.83% (95% CI, -1.28% to -0.34%) and 0.78 (95% CI, 0.66 to 0.91), respectively, for major CVD. A small increased risk for myopathy was observed in the moderate-risk stratum only, and there was no associated increased risk for liver dysfunction in any stratum. Unmeasured confounding and underascertainment of some hospitalization outcomes. Statin use in T2DM for primary prevention was associated with reductions in all-cause mortality and major CVD across the full spectrum of predicted cardiovascular risk. National Natural Science Foundation of China.


  • Open Access

    Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

    by Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić

    Sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have transformed the management of type 2 diabetes, obesity and cardiorenal disease. Beyond their established glycaemic and weight‐lowering effects, both drug classes consistently lower blood pressure (BP), a benefit that remains relatively underrecognized. This review provides an integrated synthesis of trial evidence, real‐world data and meta‐analyses examining the antihypertensive effects of SGLT2is and GLP‐1 RAs. Across cardiovascular, heart failure, renal and obesity trials, modest but clinically meaningful BP reductions have been observed in diverse populations, including individuals without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities. The totality of evidence supports the strategic incorporation of these agents into future antihypertensive frameworks, warranting further investigation in dedicated blood pressure–focused trials.


  • Open Access

    Risk of Ischaemic Stroke Varies With Antithrombotic Drugs Use in Proton Pump Inhibitor Users: A Self‐Controlled Case Series Study

    by Min Fan, Joseph E. Blais, Ian C. K. Wong, Jesse Zhao, Ka Shing Cheung, Esther W. Y. Chan, Angel Y. S. Wong, Celine S. L. Chui

    Background: The conflicting findings on the association between proton pump inhibitors (PPIs) and ischaemic stroke could be due to residual confounding. Self‐controlled case series (SCCS) can be used to avoid time‐invariant confounding. Additionally, different baseline risks of stroke should be considered, as some individuals may be prescribed PPIs for gastroprotection from bleeding with antithrombotic drugs. Methods: We identified adult patients with incident ischaemic stroke from 2003 to 2014 in Hong Kong and applied the modified SCCS. The exposure window was pre‐defined as Days 1–30, 31–60, 61–90, and 91 to the prescription end, since the PPI prescription. All other periods were referent windows. We estimated incidence rate ratios (IRR) and stratified them further using antithrombotic drugs. Results: A total of 18 170 patients were included. The IRRs for ischaemic stroke were 1.55 (95% CI: 1.00–2.42) during days 61 to 90, 1.51 (95% CI: 1.14–2.00) during days 91 to end, versus the referent window. There was no evidence of an increased risk in other risk windows versus the referent windows. In the stratified analysis, we observed an increased risk in people co‐prescribed PPIs with antithrombotic drugs in all risk periods, but no increased risks among those with PPI monotherapy versus the referent window. Conclusion: No evidence of a higher ischaemic stroke after monotherapy of PPI use. The increased risk of ischaemic stroke associated with PPIs could be due to their high baseline risk prescribed with antithrombotic drugs for primary prevention. Clinical monitoring of ischaemic stroke is recommended in these people.